RANI
Rani Therapeutics Holdings, Inc.
$0.7600
-5.24%
$94.2M
No data for this timeframe.
Vol
Market Cap$94.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders26 funds
Inst. Value$12.3M
Inst. Activity1 buys / 1 sells
Reddit Sentiment60° Warm
SEC Reports1
Press Releases2
Recent Activity
Jun 3, 2026
Insider
McKinley Kate was granted 805,500 shares
Chief Business Officer
Jun 3, 2026
Insider
Javadi Alireza was granted 805,500 shares
Chief Technical Officer
Jun 3, 2026
Insider
Imran Talat was granted 3,800,000 shares
Chief Executive Officer
May 15, 2026
SEC
Rani Therapeutics reported Q1 2026 GAAP EPS of -$0.04, beating consensus of -$0.06 by 33%, with contract revenue rising
PRESS-RELEASE — Impact 5/10
Inst.
Cerity Partners LLC — ADD
19,090 shares ($14.0K)
Inst.
BALYASNY ASSET MANAGEMENT L.P. — TRIM
5,899 shares ($4.3K)
Jun 2, 2026
short_volume
Short Volume: RANI — 58.4% short (0.4M / 0.7M)
Short: 426,675 | Exempt: 5 | TRF Vol: 730,395 | Short Ratio: 58.4% | Off-exchange volume (dark pool
Mar 26, 2026
Press
Rani Therapeutics reported its 2025 financial results alongside major corporate developments, including a $1.085 billion
Impact 8/10
Price Targets
$7.50
+886.7% upside
Strong Buy
Current $0.7601
Low $5.00
Median $7.00
High $11.00
4 analysts
$5.00
$11.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 1, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▼ -14.3% | $-0.06 — $-0.05 | 70% YoY | 3 |
| Next Q | $-0.05 ▼ -14.3% | $-0.06 — $-0.05 | 56% YoY | 3 |
| Current FY | $-0.19 ▼ -3.1% | $-0.22 — $-0.17 | 57% YoY | 3 |
| Next FY | $-0.22 ▲ +3.3% | $-0.24 — $-0.21 | -14% YoY | 3 |
Latest Reports
BULLISH
PRESS-RELEASE
5/10
Rani Therapeutics reported Q1 2026 GAAP EPS of -$0.04, beating consensus of -$0.06 by 33%, with contract revenue rising
May 15, 2026
BULLISH
Press
8/10
Rani Therapeutics reported its 2025 financial results alongside major corporate developments, including a $1.085 billion
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| RA CAPITAL MANAGEMENT, L.P. | $6.2M | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.4M | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $877.8K | — |
| BlackRock, Inc. | $409.2K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | McKinley Kate | A | $0.00 |
| Jun 3, 2026 | Javadi Alireza | A | $0.00 |
| Jun 3, 2026 | Imran Talat | A | $0.00 |
| May 28, 2026 | Bassan Abraham | A | $0.00 |
| May 28, 2026 | Rometty Lisa | A | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
26 institutional holders with $12.3M total value (16,727,283 shares) as of 2026-Q1. Top holders: ROYAL, RA, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 132 | $0.00 | 0.0% | — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8,500,000 | $6.2M | 50.8% | NEW |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4,622,567 | $3.4M | 27.7% | — |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,202,500 | $877.8K | 7.1% | — |
| 5 | BlackRock, Inc. | 556,889 | $409.2K | 3.3% | DOUBLED +338.9% |
| 6 | VANGUARD FIDUCIARY TRUST CO | 455,050 | $334.5K | 2.7% | — |
| 7 | STATE STREET CORP | 373,142 | $274.2K | 2.2% | DOUBLED +519.8% |
| 8 | CITADEL ADVISORS LLC | 276,600 | $203.2K | 1.7% | DOUBLED +229.5% |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 188,222 | $138.3K | 1.1% | — |
| 10 | Hudson Bay Capital Management LP | 153,331 | $112.7K | 0.9% | — |
| 11 | FARALLON CAPITAL MANAGEMENT LLC | 78,000 | $57.3K | 0.5% | — |
| 12 | OMERS ADMINISTRATION Corp | 76,500 | $56.2K | 0.5% | — |
| 13 | KING LUTHER CAPITAL MANAGEMENT CORP | 58,000 | $42.6K | 0.3% | ADD +75.8% |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 47,100 | $34.4K | 0.3% | — |
| 15 | Vanguard Global Advisers, LLC | 31,751 | $23.3K | 0.2% | — |
| 16 | MORGAN STANLEY | 24,370 | $17.9K | 0.1% | DOUBLED +324.8% |
| 17 | Brevan Howard Capital Management LP | 23,336 | $17.1K | 0.1% | — |
| 18 | Cerity Partners LLC | 19,090 | $14.0K | 0.1% | ADD +90.9% |
| 19 | GOLDMAN SACHS GROUP INC | 11,826 | $8.7K | 0.1% | — |
| 20 | BARCLAYS PLC | 10,246 | $7.5K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Cerity Partners LLC | ADD | 10,000 | 19,090 | +90.9% | $14.0K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 14,655 | 5,899 | -59.7% | $4.3K | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 8,500,000 | — | $11.5M | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 884,609 | 5,109,368 | +477.6% | $6.9M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 120,232 | 527,712 | +338.9% | $712.4K | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 62,442 | 387,042 | +519.8% | $522.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 17,752 | 36,607 | +106.2% | $49.4K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 6,750 | 28,677 | +324.8% | $38.7K | 2025-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 137,349 | 452,542 | +229.5% | $226.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 31,165 | 17,752 | -43.0% | $8.9K | 2025-Q3 |
| UBS Group AG | DOUBLED | 23,525 | 72,117 | +206.6% | $90.9K | 2025-Q1 |
| KING LUTHER CAPITAL MANAGEMENT CORP | ADD | 33,000 | 58,000 | +75.8% | $73.1K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 74,128 | 46,640 | -37.1% | $58.8K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 6,501 | 14,586 | +124.4% | $18.4K | 2025-Q1 |
| STATE STREET CORP | ADD | 42,042 | 62,442 | +48.5% | $85.5K | 2024-Q4 |
| KING LUTHER CAPITAL MANAGEMENT CORP | TRIM | 81,129 | 33,000 | -59.3% | $45.2K | 2024-Q4 |
| UBS Group AG | ADD | 15,709 | 23,525 | +49.8% | $32.2K | 2024-Q4 |
| STIFEL FINANCIAL CORP | NEAR_EXIT | 269,768 | 14,684 | -94.6% | $20.1K | 2024-Q4 |
| STIFEL FINANCIAL CORP | DOUBLED | 134,620 | 269,768 | +100.4% | $582.7K | 2024-Q3 |
| KING LUTHER CAPITAL MANAGEMENT CORP | ADD | 56,129 | 81,129 | +44.5% | $175.2K | 2024-Q3 |
| CITADEL ADVISORS LLC | ADD | 14,765 | 26,904 | +82.2% | $58.1K | 2024-Q3 |
| MORGAN STANLEY | ADD | 2,951 | 5,251 | +77.9% | $11.3K | 2024-Q3 |
8 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | McKinley Kate | Chief Business Officer | AWARD | 805,500 | — | — |
| Jun 3, 2026 | Javadi Alireza | Chief Technical Officer | AWARD | 805,500 | — | — |
| Jun 3, 2026 | Imran Talat | Chief Executive Officer | AWARD | 3,800,000 | — | — |
| May 28, 2026 | Bassan Abraham | Director | AWARD | 123,600 | — | — |
| May 28, 2026 | Rometty Lisa Ann | Director | AWARD | 123,600 | — | — |
| May 28, 2026 | IMRAN MIR A | Director | AWARD | 123,600 | — | — |
| May 28, 2026 | BUTEL JEAN LUC | Director | AWARD | 123,600 | — | — |
| May 28, 2026 | Bailey Vasudev Jaiprakash | Director | AWARD | 123,600 | — | — |
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 5.0/10.
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.50 mean target
+886.7% upside
Strong Buy (1.25)
$5.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7601 |
| Target Low | $5.00 |
| Target Mean | $7.50 |
| Target Median | $7.00 |
| Target High | $11.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.06 | $-0.05 | 70.4% | -14.3% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.05 | $-0.06 | $-0.05 | 55.6% | -14.3% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.19 | $-0.22 | $-0.17 | 57.0% | -3.1% | 1↑ 1↓ | $0.0B | 152.8% | 3 |
| Next FY 2027-12-31 |
$-0.22 | $-0.24 | $-0.21 | -13.8% | +3.3% | 2↑ 1↓ | $0.0B | 19.3% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.053 | |
| 7d ago | $-0.055 | +0.002 |
| 30d ago | $-0.047 | -0.007 |
| 60d ago | $-0.060 | +0.007 |
| 90d ago | $-0.160 | +0.107 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 1, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
$COCH is the future of implants and hearing
▲ 2
💬 9
⚡ 0.0
Jun 2, 2026
short_volume
Short Volume: RANI — 58.4% short (0.4M / 0.7M)
Short: 426,675 | Exempt: 5 | TRF Vol: 730,395 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 26, 2026
other
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
<p>SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-st
May 26, 2026
short_volume
Short Volume: RANI — 57.3% short (0.6M / 1.0M)
Short: 597,752 | Exempt: 26,984 | TRF Vol: 1,042,783 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
<p align="center"><em>- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with
May 14, 2026
short_volume
Short Volume: RANI — 56.5% short (0.4M / 0.8M)
Short: 425,941 | Exempt: 13,554 | TRF Vol: 754,422 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
RANI Q1 2026 Earnings After Market Close — 2026-05-13
May 11, 2026
earnings_calendar
RANI Q1 2026 Earnings After Market Close — 2026-05-11
Apr 21, 2026
short_volume
Short Volume: RANI — 64.1% short (0.3M / 0.5M)
Short: 343,778 | Exempt: 5,030 | TRF Vol: 536,369 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: RANI — 57.1% short (0.3M / 0.6M)
Short: 329,512 | Exempt: 0 | TRF Vol: 577,442 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: RANI — 76.3% short (0.4M / 0.6M)
Short: 434,251 | Exempt: 0 | TRF Vol: 569,200 | Short Ratio: 76.3% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
other
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
<p align="justify">SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA
Apr 9, 2026
short_volume
Short Volume: RANI — 68.9% short (0.4M / 0.6M)
Short: 422,144 | Exempt: 0 | TRF Vol: 612,660 | Short Ratio: 68.9% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
short_volume
Short Volume: RANI — 74.4% short (1.6M / 2.2M)
Short: 1,616,164 | Exempt: 106,135 | TRF Vol: 2,172,913 | Short Ratio: 74.4% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: RANI — 73.6% short (1.7M / 2.3M)
Short: 1,716,132 | Exempt: 104,787 | TRF Vol: 2,332,517 | Short Ratio: 73.6% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
<p align="center"><em>- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed